Drug Profile
Tifalibep - Affibody
Alternative Names: ABY-039Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Affibody
- Class Small molecules
- Mechanism of Action Neonatal Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 18 Jun 2020 Affibody terminates the development and marketing agreement with Alexion Pharmaceuticals to co-develop ABY 039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases
- 15 Jun 2020 Affibody completes a phase-I clinical trials in Autoimmune disorders (In volunteers) in United Kingdom